Lyell Immunopharma, Inc. (LYEL)
NASDAQ: LYEL · Real-Time Price · USD
0.4843
-0.0537 (-9.98%)
At close: Apr 1, 2025, 4:00 PM
0.4900
+0.0057 (1.18%)
After-hours: Apr 1, 2025, 7:29 PM EDT

Lyell Immunopharma Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019
Net Income
-342.99-234.63-183.12-250.22-204.47
Upgrade
Depreciation & Amortization
19.6320.2518.0213.624.29
Upgrade
Loss (Gain) From Sale of Assets
1.341.510.11.21-4.88
Upgrade
Asset Writedown & Restructuring Costs
138.48----
Upgrade
Loss (Gain) From Sale of Investments
-1.713.331.1538.350.54
Upgrade
Stock-Based Compensation
33.1447.0881.9262.233.26
Upgrade
Other Operating Activities
-7.17-4.65-5.624.5710.72
Upgrade
Change in Accounts Payable
-3.231.460.670.09-0.28
Upgrade
Change in Unearned Revenue
---84.65-10.51-7.76
Upgrade
Change in Other Net Operating Assets
0.111.961.9714.437.7
Upgrade
Operating Cash Flow
-162.39-163.69-169.56-126.25-160.87
Upgrade
Capital Expenditures
-0.46-2.69-24.28-65.5-51.48
Upgrade
Cash Acquisitions
-31.35----
Upgrade
Investment in Securities
154.23186.7312.74-56.07-222.04
Upgrade
Investing Cash Flow
122.42184.05-11.54-121.57-273.52
Upgrade
Issuance of Common Stock
1.42.211.1401.240.37
Upgrade
Repurchase of Common Stock
-0.08-0.46-0.46--11.81
Upgrade
Financing Cash Flow
1.331.7410.64401.24476.79
Upgrade
Net Cash Flow
-38.6422.1-170.46153.4242.4
Upgrade
Free Cash Flow
-162.86-166.38-193.83-191.75-212.36
Upgrade
Free Cash Flow Margin
-266980.33%-127984.62%-228.89%-1800.50%-2737.94%
Upgrade
Free Cash Flow Per Share
-0.62-0.66-0.78-1.41-16.02
Upgrade
Levered Free Cash Flow
-67.56-90.36-53.9-129.82-128
Upgrade
Unlevered Free Cash Flow
-67.56-90.36-53.9-129.82-128
Upgrade
Change in Net Working Capital
-16.961.5712.736.66-23.25
Upgrade
Updated Mar 11, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q